Article

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Versus Systemic Therapy in Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis

2026-01-23

Abstract excerpt

<h4>Background: </h4> The optimal treatment for unresectable intrahepatic cholangiocarcinoma (iCCA) remains uncertain. Hepatic arterial infusion chemotherapy (HAIC) aims to increase local drug concentration and tumor response. Methods Following PRISMA 2020 guidelines and PROSPERO registration (CRD420251128740), we searched major databases up to March 2025. Included: observational comparative studies of HAIC (alone...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 17540d13-27be-5bc8-902a-c7de37d49d4a
DOI: 10.20944/preprints202601.1785.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Versus Systemic Therapy in Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-AnalysisDOI 10.20944/preprints202601.1785.v1Read

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma: a real-world studySemantic proximity Read

Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity Read

Neoadjuvant therapy could improve survival outcomes of locally advanced biliary tract cancer by increasing opportunities for curative resection: a systematic review and meta-analysisSemantic proximity Read

Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.Semantic proximity Read

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.Semantic proximity Read

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.Semantic proximity Read

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.Semantic proximity Read

Systemic treatment of advanced or recurrent biliary tract cancer.Semantic proximity Read

Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center StudySemantic proximity Read

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.Semantic proximity Read

Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinomaSemantic proximity Read

Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombusSemantic proximity Read